For that, prospective trials with larger patient cohorts recording metastatic patterns and B2M mutation status are required, which shall reveal whether the good survival of B2M-mutant M1 MSI cancer patients under ICB reflects the biology of the tumor cells, or indicates treatment response. Here, B2M is linked to cancer.